Treatment with demethylating agent, 5-aza-2′-deoxycytidine enhances therapeutic HPV DNA vaccine potency
- 24 February 2009
- Vol. 27 (32) , 4363-4369
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3Clinical Cancer Research, 2008
- Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effectsVaccine, 2008
- Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccinationJournal of Molecular Medicine, 2008
- Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell–Mediated Antitumor Immunity Induced by DNA VaccinationClinical Cancer Research, 2008
- Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancerBMC Cancer, 2008
- Generation and characterization of a preventive and therapeutic HPV DNA vaccineVaccine, 2008
- Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cellsExpert Review of Vaccines, 2007
- Intranuclear disposition of exogenous DNA in vivo: Silencing, methylation and fragmentationFEBS Letters, 2006
- Comparison of HPV DNA vaccines employing intracellular targeting strategiesGene Therapy, 2004
- DNA VACCINESAnnual Review of Immunology, 1997